Loading organizations...
§ Private Profile · Wuhan, Hubei, China
Gene therapy company focused on ophthalmic diseases and blindness.
Neurophth Therapeutics has raised $217.0M across 3 funding rounds.
Neurophth Therapeutics has raised $217.0M in total across 3 funding rounds.
Neurophth Therapeutics has raised $217.0M in total across 3 funding rounds.
Neurophth Therapeutics's investors include Hubei KTLC, Wuhan, Wuhan Hi-Tech Holding Group, Wuhan Optical Valley Financial Holding Group, Yangtze River-CMB International Industry Fund, CMG-SDIC Capital, Silicon Paradise Asset Management, Yangtze River Industry Fund, Hongshan Capital Group (Sequoia Capital China), CMB International, Lane Zhao, Grand Mount Capital.
Neurophth Therapeutics has raised $217.0M across 3 funding rounds. Most recently, it raised $95.0M Series C in August 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 11, 2023 | $95M Series C | Hubei KTLC, Wuhan, Wuhan HI Tech Holding Group, Wuhan Optical Valley Financial Holding Group, Yangtze River CMB International Industry Fund | CMG SDIC Capital, Silicon Paradise Asset Management, Yangtze River Industry Fund | Announced |
| Nov 23, 2021 | $60M Series C | CMG SDIC Capital, Hongshan Capital Group (Sequoia Capital China) | CMB International | Announced |
| Feb 9, 2021 | $62M Series B | Lane Zhao | Grand Mount Capital, Harvest Capital, Trency GU, Northern Light Venture Capital, Oriza Holdings | Announced |